EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Dexin Corporation (3349) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Dexin Corporation TWD 18.23, price TWD 19.90, upside -8.4%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Technology · TW

DC Thin data Sep 24, 2026

Dexin Corporation

3349 · TWO

NeutralThe stock looks roughly fairly valued with average quality.

·Fair value 18.23 TWD · Fairly valued (−8%)
!Quality 58/100
!Weak Growth (revenue 5y −10.0 %/yr)
!Loss-making · -14.3% net margin (TTM)
✓generates free cash flow
!Mixed vs. peers (5/10)
!Narrow moat 13/100
!Evidence only low, so the estimate is less certain
!Weak on valuation: 22 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

32.00 TWD 12.20 TWD Fair Value 18.23 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 12.20 TWD – 32.00 TWD · fair‑value band 14.75 TWD – 21.94 TWD · the 19.90 TWD price screens above the 18.23 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Dexin in your weekly email

Every Wednesday you see whether Dexin is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dexin Corporation engages in the design, development, engineering, manufacture, and sale of entertainment interface devices in Taiwan and internationally.

Show more

Dexin Corporation engages in the design, development, engineering, manufacture, and sale of entertainment interface devices in Taiwan and internationally. The company offers esports peripherals, such as e-sports mouse, controllers, keyboards, and gaming mouse pad, as well as stylus; and optical products comprising camera modules, vehicle camera modules and media cameras. It also is involved in the provision of industrial design, research design development, product and manufacture engineering design development, and other customized project design and development services for original equipment and design manufacturers. The company was founded in 1997 and is headquartered in New Taipei City, Taiwan..

Stock analysis

Dexin Corporation (3349) currently trades at 19.90 TWD, while our model-based Fair Value estimate is 18.23 TWD, implying the stock looks roughly 9.1% fairly valued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of 24.21 TWD per share, and 6 of the 10 models we run sit above the 19.90 TWD price.

Bear case: the Multiples group reads lowest at 4.69 TWD, and 4 of the 10 models stay below the price. Evidence for this calculation is low.

Scenario range: 14.75 TWD (bear) to 21.94 TWD (bull), the price of 19.90 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Technology sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Dexin Corporation reported revenue of 479M TWD in FY2025 versus 1.2B TWD in FY2021, a compound −21.0%/yr. Reported net income was −43.9M TWD in FY2025.

Key figures

Market cap 1.1B TWD (≈ $34.1M) · P/S ratio 2.45 · EPS (TTM) −1.02 TWD · Net margin −9.2% · Return on equity −20.4% · Return on assets (EBIT) −6.5% · Operating margin −41.4% · Revenue (TTM) 443M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Technology peers we cover trades at −33% fair-value upside, at −8%, 3349 screens cheaper than that median.

Fair Value models

Bear 14.75 TWD Fair Value 18.23 TWD Bull 21.94 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 19.05 TWD 24.37 TWD 33.90 TWD 79
Growth DCF 19.67 TWD 24.79 TWD 33.27 TWD 77
5Y EBITDA Exit 10.39 TWD 10.83 TWD 11.42 TWD 74
All 10 models by family
DCF Models
FCF DCF 19.05 TWD 24.37 TWD 33.90 TWD 79
5Y Revenue Exit 17.91 TWD 23.86 TWD 32.50 TWD 71
5Y EBITDA Exit 10.39 TWD 10.83 TWD 11.42 TWD 74
10Y Revenue Exit 17.92 TWD 22.32 TWD 27.00 TWD 66
10Y EBITDA Exit 13.80 TWD 14.44 TWD 14.92 TWD 67
Multiples
EV/EBITDA 4.65 TWD 4.69 TWD 4.73 TWD 64
EV/Revenue 18.30 TWD 24.21 TWD 30.11 TWD 52
Asset-Based
NCAV (Graham) 3.75 TWD 5.03 TWD 7.50 TWD 51
Growth DCF
Growth DCF 19.67 TWD 24.79 TWD 33.27 TWD 77
Rev-Margin DCF 17.91 TWD 24.21 TWD 31.95 TWD 71

Open the full fair value analysis →

Notify me when 3349 reaches fair value

Put 3349 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 62 · Market factors (momentum, volatility) 45

Profitability 20
Margins and returns on capital today
Quality Growth 67
Are margins and returns improving?
Cashflow 74
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 69
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 26
Distance to the 52-week high (market factor)
Net Issuance 12
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.9% (2020) → −6.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +0.2% a year for the price.

Watch 3349, get fair value alerts →

Compare Dexin Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Computer Hardware · 220 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside −5% · Above median
Profitability
Return on assets −5% · Bottom 25%
Net margin (TTM) −14% · Bottom 25%
Operating margin (TTM) −41% · Bottom 25%
Growth and dividend
Revenue growth −37% · Bottom 25%

Valuation Multiplesvs Computer Hardware median · lower = cheaper

P/B 0.10× · Cheapest 25%
P/S (TTM) 0.08× · Cheapest 25%
P/FCF 0.5× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)22 · sector 0
FUTURE (revenue growth)0 · sector 59
PAST (return on equity)0 · sector 26
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Computer Hardware stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Dell Technologies Inc DELL $548.92 $195.72 −64%
Arista Networks, Inc ANET $203.47 $161.72 −21%
Western Digital Corporation WDC $473.69 $53.53 −89%
Wiwynn Corporation 6669 2,115 TWD 1,065 TWD −50%
Hangzhou Hikvision Digital Technology Co 002415 ¥33.18 ¥46.76 +41%
Quanta Computer Inc 2382 338.50 TWD 228.14 TWD −33%
Lenovo Group 0992 HK$36.92 HK$33.70 −9%
Dawning Information Industry Co 603019 ¥84.67 ¥35.54 −58%
Everpure, Inc P $110.89 $51.46 −54%
HP Inc HPQ $32.16 $51.90 +61%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Dexin Corporation Fair Value". https://www.fairvalue-calculator.com/stock/3349

Frequently asked questions

Is Dexin Corporation (3349) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 18.23 TWD versus a price of 19.90 TWD, about −8% upside (fairly valued).
What is the fair value of 3349?
Our model-based fair value for Dexin Corporation is 18.23 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 19.90 TWD.
What is the quality score of 3349?
Dexin Corporation has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dexin Corporation (3349)?
Our model-based price target is the fair value of 18.23 TWD (as of Sep 24, 2026) from 10 valuation models. Cautious scenario 14.75 TWD, optimistic scenario 21.94 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Dexin Corporation stock forecast for 2026?
Our models put fair value at 18.23 TWD, about −8% upside versus a price of 19.90 TWD (fairly valued). Cautious scenario 14.75 TWD, optimistic scenario 21.94 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Dexin Corporation (3349)?
Dexin Corporation reported trailing-twelve-month revenue of about 443M TWD (latest available figure, as of Sep 24, 2026).
What growth is priced into Dexin Corporation (3349)?
For today's price to be fair in a discounted-cash-flow model, Dexin Corporation would have to grow free cash flow by +1.8 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -10.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 3349 use?
Our models discount Dexin Corporation at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dexin Corporation that is +1.8 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Dexin Corporation (3349) delivered so far?
Over the past 5 years revenue at Dexin Corporation grew -10.0 % a year. The price currently implies +1.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dexin Corporation (3349) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Dexin Corporation (+1.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dexin Corporation (3349)?
The free-cash-flow yield on the price is 7.61 %: that much free cash flow Dexin Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dexin Corporation (3349)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dexin Corporation it is 18.23 TWD per share (as of Sep 24, 2026), against a price of 19.90 TWD. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Dexin Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 3349 trades above its calculated fair value: price 19.90 TWD, fair value 18.23 TWD, a gap of about −8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3349?
No. The price is what the market pays today (19.90 TWD); the fair value is what the company's own numbers justify (18.23 TWD). For Dexin Corporation the two are 1.67 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Dexin Corporation worth?
The market values Dexin Corporation at about 1.1B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 19.90 TWD; our models calculate a fair value of 18.23 TWD per share.
What do the bullish and bearish scenarios say about 3349?
Our models span a range for Dexin Corporation: cautious scenario 14.75 TWD, base 18.23 TWD, optimistic 21.94 TWD per share (as of Sep 24, 2026, price 19.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dexin Corporation (3349)?
Balance-sheet figures for Dexin Corporation (as of Sep 24, 2026): return on equity −20.4%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 3349 from its 52-week high?
Dexin Corporation trades at 19.90 TWD, about 38% below its 52-week high of 32.00 TWD and 12% above the low of 17.70 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 18.23 TWD is for.
Which stocks are comparable to Dexin Corporation?
From the same area (Technology) we also value Dell Technologies Inc, Arista Networks, Inc, Western Digital Corporation, Wiwynn Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dexin Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 19.90 TWD, calculated fair value 18.23 TWD (−8%), Quality Score 58/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3349 calculated?
We run Dexin Corporation through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 18.23 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Dexin Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dexin Corporation (3349)?
The closing price on Sep 24, 2026 was 19.90 TWD. Our model-based fair value is 18.23 TWD, about −8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dexin Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Dexin Corporation

How large is the market capitalisation of Dexin Corporation (3349)?
The market capitalisation of Dexin Corporation is 1.1B TWD (≈ $34.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dexin Corporation (3349)?
The price-to-sales ratio of Dexin Corporation is 2.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dexin Corporation (3349)?
Earnings per share at Dexin Corporation are −1.02 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Dexin Corporation (3349)?
The net margin of Dexin Corporation is −9.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dexin Corporation (3349)?
The return on equity (ROE) of Dexin Corporation is −20.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dexin Corporation (3349)?
On an EBIT basis the return on assets of Dexin Corporation is −6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dexin Corporation (3349)?
The operating margin of Dexin Corporation is −41.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dexin Corporation (3349)?
Revenue at Dexin Corporation is growing −37.1% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Dexin Corporation (3349) hold?
Dexin Corporation holds more cash than debt, 6.7M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Dexin Corporation in the live analysis

One click puts Dexin Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.